Vnitr Lek 2015, 61(Suppl 4):24-29

Possibilities of IFN-free therapy of hepatitis C

Petr Husa
Klinika infekčních chorob Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Petr Husa, CSc.

Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications and extraordinarily favorable safety profile. Primarily, it is necessary to pay attention to drug-drug interactions. However they are well documented and successfully resolvable already in general clinical practice. Current possibilities of interferon-free therapy represent combinations of sofosbuvir with other DAA or with ribavirin and combination of paritaprevir boosted by ritonavir + ombitasvir ± dasabuvir (3D combination).

Keywords: chronic hepatitis C; paritaprevir; ombitasvir; dasabuvir; ribavirin

Received: November 9, 2015; Published: August 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P. Possibilities of IFN-free therapy of hepatitis C. Vnitr Lek. 2015;61(Supplementum 4):24-29.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014; 60(2): 392-420. Erratum in: J Hepatol 2014; 61(1): 183-184. Dostupné z DOI: <http://doi:10.1016/j.jhep.2013.11.003>. Go to original source... Go to PubMed...
    2. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63(1): 199-236. Dostupné z DOI: <http://doi:10.1016/j.jhep.2015.03.025>. Go to original source... Go to PubMed...
    3. AASLD recommendation for testing, managing, and treating hepatitis C. Dostupné z WWW: <http://www.hcvguidelines.org>.
    4. Harvoni: Souhrnu údajů o přípravku (SPC). Datum revize textu 06.2015. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003850/WC500177995.pdf>.
    5. Urbánek P, Husa P, Šperl J et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Dostupné z WWW: <http://www.ces-hep.cz/file/415/guidelines-hcv-2015-chs-sil.pdf>.
    6. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1594-1603. Go to original source... Go to PubMed...
    7. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370(21): 1983-1992. Go to original source... Go to PubMed...
    8. Wyles DL, Sulkowski MS, Eron JJ et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. Hepatology 2014; 60(Suppl 1): 1136A.
    9. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1604-1614. Go to original source... Go to PubMed...
    10. Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147(2): 359-365. Go to original source... Go to PubMed...
    11. Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370(21): 1973-1982. Go to original source... Go to PubMed...
    12. Pol S, Reddy KR, Baykal T et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology 2014; 60(Suppl 1): 1129A. Go to original source...
    13. Urbánek P. Exviera, Viekirax. Gastroent Hepatol 2015; 69(1): 75-80. Go to original source...
    14. University of Liverpool. Drug interactions charts. Dostupné z WWW: <http://www.hep-druginteractions.com>.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.